NFκB activation and drug sensitivity in human neoplastic cells treated with anthracyclines

Acta Poloniae Pharmaceutica - Drug Research

Volumn 65, Issue 2, 2008, Pages 267-271

  Gruber, Beata M ^a   Anuszewska, Elzbieta L ^a   Bubko, Irena ^a   Kasprzycka Guttman, Teresa ^a   Misiewicz, Irena ^a   Skupińska, Katarzyna ^a   Fokt, Izabela ^b   Piebe, Waldemar ^b  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Anthracyclines; Cytotoxicity; NF B

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANNAMYCIN; ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; PYRROLIDINE DITHIOCARBAMATE; SYNAPTOTAGMIN I; WP 903; ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SPECIFICITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IC 50; DRUG ANTAGONISM; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; NEOPLASMS; NF-KAPPA B;

EID: 45849111801     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Sen R., Baltimore D.: Cell 47, 921 (1986).
2. Bours V., Bentires - Alj M., Hellin A.C., Viatour P., Robe P., Delhalle S., Benoit V, Merville M.P.: Biochem. Pharmacol. 60, 1085 (2000).
3. Shishodia S., Aggarwal B.B.: Biochem. Pharmacol. 68, 1071 (2004).
4. Wu J.T., Kral J.G.: J. Surg. Res. 123, 158 (2005).
5. Mayo M.W., Baldwin A.S.: Biochim. Biophys. Acta 1470, M 55 (2000).
6. Tabata M., Tabata R., Grabowski D.R., Bukowski R.M., Ganapathi M.K., Ganapathi R.: J. Biol. Chem. 276, 8029 (2001).
7. Boland M.P., Fitzgerald K.A., O'Neill L.A.J.: J. Biol. Chem. 275, 25231 (2000).
8. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T. et al.: Clin. Cancer Res. 10, 7645 (2004).
9. Andriollo M., Favier A., Guiraud P.: Arch. Biochem. Biophys. 413, 75 (2003).
10. Ashikawa A., Shishodia S., Fokt I., Priebe W., Aggarwal B.B.: Biochem. Pharmacol. 67, 353 (2004).
11. Anuszewska E.L., Gruber B.M., Koziorowska J.H.: Biochem. Pharmacol. 54, 597 (1997).
12. Gruber B.M., Anuszewska E.L.: Toxicol. in Vitro 16, 663 (2002).
13. Bowie A., O'Neill L.A.J.: Biochem. Pharmacol. 59, 13 (2000).
14. Gruber B.M., Anuszewska E.L., Bubko I., Goździk A., Fokt I., Priebe W.: Arch. Immunol. Ther. Exp. 55, 1 (2007).
15. Gruber B.M., Anuszewska E.L., Priebe W.: Folia Histochem. Cytobiol. 42, 127 (2004).
16. Gruber B.M., Anuszewska E.L., Bubko I., Kasprzycka-Guttman T., Misiewicz I., Skupińska K., Priebe W., Fokt I.: Acta Pol. Pharm.-Drug Res. 62, 17 (2005).
17. Bian X., Mc Allister-Lucas L.M., Shao F., Schumacher K.R., Feng Z., Porter A.G., Castle V.P., Opipari A.W., Jr.: J. Biol. Chem. 52, 48921 (2001).
18. Ma M.H. et al.: Clin. Cancer Res. 9, 1136 (2003).